Quantum Genomics Stock price

Equities

ALQGC

FR0011648971

Biotechnology & Medical Research

Real-time Euronext Paris 06:39:00 2024-03-28 am EDT 5-day change 1st Jan Change
0.1028 EUR -1.15% Intraday chart for Quantum Genomics +0.39% -3.02%
Sales 2024 * - Sales 2025 * - Capitalization 3.62M 3.91M
Net income 2024 * -3M -3.24M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * 8.7M 9.39M Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.16 x
P/E ratio 2025 *
-
Employees 3
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.23%
More Fundamentals * Assessed data
Dynamic Chart
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Global markets live: Microsoft, Raytheon, JPMorgan, Credit Suisse... Our Logo
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Quantum Genomics Ousts Board President; CEO Named Successor MT
Quantum Genomics' Hypertension Drug Firibastat Fails to Show Significant Efficacy in Late-Stage Trial MT
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments CI
Certain Shares of Quantum Genomics Société Anonyme are subject to a Lock-Up Agreement Ending on 24-OCT-2022. CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Quantum Genomics Société Anonyme(ENXTPA:ALQGC) dropped from S&P Global BMI Index CI
Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board CI
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH CI
Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Quantum Genomics Société Anonyme announced that it expects to receive €15 million in funding from Otium Capital, Vatel Capital SAS CI
More news
1 day-1.15%
1 week+0.39%
Current month-0.19%
1 month-1.15%
3 months-0.19%
6 months-37.70%
Current year-3.02%
More quotes
1 week
0.10
Extreme 0.1024
0.11
1 month
0.10
Extreme 0.101
0.13
Current year
0.10
Extreme 0.096
0.16
1 year
0.08
Extreme 0.0804
0.21
3 years
0.08
Extreme 0.0804
6.19
5 years
0.08
Extreme 0.0804
6.19
10 years
0.08
Extreme 0.0804
14.27
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 -
Founder 56 05-12-22
Director of Finance/CFO - 18-06-30
Members of the board TitleAgeSince
Founder 56 05-12-22
Director/Board Member 66 -
Chief Executive Officer 63 -
More insiders
Date Price Change Volume
24-03-28 0.1028 -1.15% 1 995
24-03-27 0.104 +1.36% 10,564
24-03-26 0.1026 -0.77% 23,680
24-03-25 0.1034 -2.45% 16,548
24-03-22 0.106 +3.52% 24,570

Real-time Euronext Paris, March 28, 2024 at 06:39 am EDT

More quotes
Quantum Genomics is a biotechnology company that specializes in the research and development of drugs for the treatment of cardiovascular diseases such as high blood pressure and heart failure. All sales are abroad.
More about the company
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.104 EUR
Average target price
0.1 EUR
Spread / Average Target
-3.85%
Consensus
  1. Stock
  2. Equities
  3. Stock Quantum Genomics - Euronext Paris